# A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

> **NCT02309892** · PHASE1 · TERMINATED · sponsor: **Helix BioPharma Corporation** · enrollment: 14 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** L-DOS47

## Key facts

- **NCT ID:** NCT02309892
- **Lead sponsor:** Helix BioPharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-20
- **Primary completion:** 2019-08-19
- **Final completion:** 2019-09-20
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Slow enrolment - standard of care evolved over the duration of the study such that treatment regimen employed in the study was no longer current standard of care for first line resulting in recruitment challenges.
- **Last updated:** 2024-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02309892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02309892, "A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02309892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*